Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Tezspire
| Field | Information |
|---|---|
| Medication Name | Tezspire |
| Generic Name | Tezepelumab-ekko |
| Purpose | Add-on maintenance treatment for severe asthma. |
| Mechanism of Action | Tezepelumab is a human monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a key role in asthma inflammation. |
| Dosage Forms | Solution for subcutaneous injection |
| Available Strengths | 210 mg/1.4 mL (150 mg/mL) in a single-dose pre-filled syringe or autoinjector |
| Dosage Frequency | Administered subcutaneously once every 4 weeks. |
| Common Side Effects | Sore throat, arthralgia (joint pain), back pain, fatigue, injection site reactions. |
| Serious Side Effects | Hypersensitivity reactions (including anaphylaxis), serious allergic reactions. |
| Drug Interactions | No significant drug interactions reported in clinical trials. |
| Important Notes | Tezspire is not for use to treat acute asthma symptoms or acute exacerbations. Patients should continue to take their other asthma medications unless otherwise directed by their healthcare provider. |
| Storage | Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. |
| Missed Dose | Administer the injection as soon as possible, continuing with the every 4-week schedule. |
| Alternatives | Omalizumab (Xolair), Mepolizumab (Nucala), Reslizumab (Cinqair), Benralizumab (Fasenra), Dupilumab (Dupixent) |
Tezspire Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Omalizumab (Xolair) | Anti-IgE monoclonal antibody | For allergic asthma; reduces free IgE. |
| Mepolizumab (Nucala) | Anti-IL-5 monoclonal antibody | For eosinophilic asthma; reduces eosinophils. |
| Reslizumab (Cinqair) | Anti-IL-5 monoclonal antibody | For eosinophilic asthma; requires IV infusion. |
| Benralizumab (Fasenra) | Anti-IL-5 receptor alpha monoclonal antibody | For eosinophilic asthma; causes direct depletion of eosinophils. |
| Dupilumab (Dupixent) | Anti-IL-4 receptor alpha monoclonal antibody | Targets IL-4 and IL-13 pathways; for eosinophilic asthma or oral steroid-dependent asthma. |
Tezspire Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Sore throat | Hypersensitivity reactions (anaphylaxis, allergic reactions) |
| Arthralgia (joint pain) | Serious allergic reactions |
| Back pain | |
| Fatigue | |
| Injection site reactions (pain, redness, swelling) |
Tezspire Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Severe Asthma | 210 mg | 210 mg every 4 weeks | Administered subcutaneously by a healthcare provider or self-administered after training. |
Tezspire Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $50 |
| Without Insurance (U.S.) | $4160 |
| From Canada | $3055 |
